Acetylcholinesterase inhibitors and gait: a steadying hand?
Cognitive impairment, complex movement disorders, and high risk of falls are all inter-related, levodopaunresponsive symptoms in patients with advanced Parkinson's disease. Although Parkinson's disease is conventionally viewed as a motor syndrome that results from nigrostriatal dopaminergic denervation, there is also an intricate interplay between multisystem degeneration and neurotransmitter defi cits other than the loss of nigrostriatal dopaminergic neurons, especially defi cits in the cholinergic system. The degeneration of neurons in the nucleus basalis of Meynert (the source of cholinergic innervation of the cerebral cortex) is a hallmark of latestage parkinsonian dementia and is at least as severe as that involved in Alzheimer's disease. 1 Although the pathological importance of this degeneration was fi rst recognised by Lewy in his report on a series of patients with Parkinson's disease, neuron loss in the nucleus basalis of Meynert was not quantifi ed until the 1980s (with depletion of up to 80%). 2 However, cholinergic denervation also occurs in patients with Parkinson's disease without dementia. Therefore, although it might make specifi c contributions to the clinical phenotype of Parkinson's disease dementia, the eff ect of denervation seems diverse, for instance, central limbic cholinergic denervation might be associated with the progressive impairment of odour identifi cation.
1 Recent evidence also indicates that subcortical cholinergic denervation (probably caused by degeneration of brainstem pedunculopontine nucleus [PPN] neurons) might be associated with dopaminerefractory gait and balance impairments (including falls) in Parkinson's disease.
1 Indeed, the role of cholinergic neurons within the mesencephalic locomotor area (including the PPN and the cuneiform nucleus) in gait has been emphasised by a range of studies in healthy people and preclinical studies of lesioned cats and primates.
3,4 Trials of PPN-directed deep-brain stimulation in human beings have mostly targeted freezing of gait, and have yielded inconsistent results. 5 In animal models, cholinergic-striatal disruption of attentional-motor pathways in the basal forebrain is a major cause of falls. Additional losses of cholinergic neurons in the PPN can worsen posture and gait control. Thus the correlations between the various patterns of cholinergic denervation and clinical phenotypes in Parkinson's disease remain to be studied. The association between cortical and subcortico-mesencephalic cholinergic defi cit in patients with Parkinson's disease without dementia with high-level gait disorders (such as freezing of gait), postural instability, falls, coupled with dysexecutive syndrome, and apathy warrant further research. 6 In The Lancet Neurology, Emily Henderson and colleagues 7 report fi ndings from the randomised ReSPonD trial, which studied the eff ects of 32 weeks of highdose rivastigmine versus placebo in 130 patients with Parkinson's disease without dementia. Patients had a high fall rate (median fi ve falls) in the year before inclusion and so were a population at risk of future falls. Patients assigned to rivastigmine showed better gait stability at 32 weeks than did those assigned to placebo. Rivastigmine was associated with a 28% (95% CI 11-42; p=0·002) greater reduction in adjusted step time variability (used to measure gait instability 8 ) during an 18 m walking task compared with placebo. However, step time variability in a simple dual task (walking while listing words beginning with the same letter) was only somewhat improved (21% [1-38]; p=0·045), and there was no signifi cant diff erence between groups in the high-level cognitive dual task (walking while listing words beginning with alternating letters; 19% [-9 to 40]; p=0·17). The rivastigmine group had signifi cantly fewer falls than did the placebo group over the trial period (falls per month 1·4 [SD 2·47] vs 2·4 [4·40], respectively). However, the drug did not have signifi cant eff ects on episodes of freezing of gait or assessed neuropsychological outcomes (ie, fear of falling, anxiety, and depression).
Research from Giladi and colleagues has emphasised the rationale for assessment of cholinergic drugs in patients with Parkinson's disease with high-level gait disorders. 9 However, in their open-label pilot study 5 mg per day of rivastigmine did not signifi cantly reduce gait rhythm disorders, despite improved general mobility and lower anxiety being reported by patients. Thus, high-dose rivastigmine seems to have a specifi c eff ect on postural instability. These results have been long awaited, since there are no available pharmacological treatments for poor postural stability in Parkinson's disease.
A high number of adverse events were reported by both groups in the ReSPonD. 7 Although gastrointestinal disorders were probably causally related to rivastigmine, many of the adverse events could have been due to the high level of comorbidities in the study population. Importantly, cardiac adverse events were not more frequent in the rivastigmine than in the placebo group and the groups did not diff er signifi cantly in Movement Disorder Society-Unifi ed Parkinson's Disease Rating Scale (MDS-UPDRS) total score after 32 weeks. Notably, no worsening of resting tremor was noted despite rivastigmine possibly leading to an imbalance within the striatum between lower dopaminergic and higher cholinergic neurotransmission, which is associated with resting tremor.
Some questions are yet to be resolved. In particular, did rivastigmine have diff erent eff ects on static postural stability (assessed by the retropulsion test, item 3.12 of the MDS-UPDRS) versus dynamic postural stability (strideto-stride variability during gait)? Although Henderson and colleagues assessed mood with the Geriatric Depression Scale, it would have been useful to investigate apathy because an earlier double-blind, placebo-controlled study of patients with Parkinson's disease with pre-dementia apathy showed that rivastigmine treatment was associated with a lower overall apathy score and caregiver burden and greater intellectual curiosity and action initiation. 10 Overall, the fi ndings of the ReSPonD trial provide valuable arguments in favour of high-dose rivastigmine treatment in patients with high-level gait disorders. These fi ndings must now be confi rmated in a larger cohort of patients with a range of cognitive and behavioural profi les, and taking into account the dose eff ect, and the long-term risk-benefi t balance.
